NM_000817.3:c.1252G>T

Variant summary

Our verdict is Benign. The variant received -7 ACMG points: 0P and 7B. BP4_ModerateBS1_SupportingBS2

The NM_000817.3(GAD1):​c.1252G>T​(p.Val418Phe) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000478 in 1,614,030 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Uncertain significance in ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V418I) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0010 ( 1 hom., cov: 32)
Exomes 𝑓: 0.00042 ( 2 hom. )

Consequence

GAD1
NM_000817.3 missense

Scores

3
15

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:5B:2

Conservation

PhyloP100: 1.75

Publications

4 publications found
Variant links:
Genes affected
GAD1 (HGNC:4092): (glutamate decarboxylase 1) This gene encodes one of several forms of glutamic acid decarboxylase, identified as a major autoantigen in insulin-dependent diabetes. The enzyme encoded is responsible for catalyzing the production of gamma-aminobutyric acid from L-glutamic acid. A pathogenic role for this enzyme has been identified in the human pancreas since it has been identified as an autoantigen and an autoreactive T cell target in insulin-dependent diabetes. This gene may also play a role in the stiff man syndrome. Deficiency in this enzyme has been shown to lead to pyridoxine dependency with seizures. Alternative splicing of this gene results in two products, the predominant 67-kD form and a less-frequent 25-kD form. [provided by RefSeq, Jul 2008]
GAD1 Gene-Disease associations (from GenCC):
  • early infantile epileptic encephalopathy
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • developmental and epileptic encephalopathy 89
    Inheritance: AR Classification: STRONG, LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)
  • spastic quadriplegic cerebral palsy
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
  • cerebral palsy, spastic quadriplegic, 1
    Inheritance: AR Classification: LIMITED Submitted by: Ambry Genetics
  • neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities
    Inheritance: AR Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -7 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.19945809).
BS1
Variant frequency is greater than expected in population amr. GnomAd4 allele frequency = 0.00101 (153/152204) while in subpopulation AMR AF = 0.0036 (55/15286). AF 95% confidence interval is 0.00284. There are 1 homozygotes in GnomAd4. There are 80 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAdExome4 at 2 AR gene

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_000817.3. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
GAD1
NM_000817.3
MANE Select
c.1252G>Tp.Val418Phe
missense
Exon 13 of 17NP_000808.2

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
GAD1
ENST00000358196.8
TSL:1 MANE Select
c.1252G>Tp.Val418Phe
missense
Exon 13 of 17ENSP00000350928.3
GAD1
ENST00000488724.5
TSL:1
n.352G>T
non_coding_transcript_exon
Exon 2 of 6
GAD1
ENST00000493875.5
TSL:1
n.*86G>T
non_coding_transcript_exon
Exon 13 of 17ENSP00000434696.1

Frequencies

GnomAD3 genomes
AF:
0.00101
AC:
153
AN:
152086
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00106
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00360
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000193
Gnomad SAS
AF:
0.00187
Gnomad FIN
AF:
0.000378
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000456
Gnomad OTH
AF:
0.00431
GnomAD2 exomes
AF:
0.000541
AC:
136
AN:
251472
AF XY:
0.000589
show subpopulations
Gnomad AFR exome
AF:
0.00117
Gnomad AMR exome
AF:
0.000405
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000739
Gnomad NFE exome
AF:
0.000519
Gnomad OTH exome
AF:
0.00147
GnomAD4 exome
AF:
0.000423
AC:
619
AN:
1461826
Hom.:
2
Cov.:
30
AF XY:
0.000448
AC XY:
326
AN XY:
727232
show subpopulations
African (AFR)
AF:
0.00131
AC:
44
AN:
33480
American (AMR)
AF:
0.000827
AC:
37
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39698
South Asian (SAS)
AF:
0.000985
AC:
85
AN:
86258
European-Finnish (FIN)
AF:
0.000431
AC:
23
AN:
53418
Middle Eastern (MID)
AF:
0.00485
AC:
28
AN:
5768
European-Non Finnish (NFE)
AF:
0.000297
AC:
330
AN:
1111952
Other (OTH)
AF:
0.00118
AC:
71
AN:
60392
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.448
Heterozygous variant carriers
0
36
72
108
144
180
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00101
AC:
153
AN:
152204
Hom.:
1
Cov.:
32
AF XY:
0.00108
AC XY:
80
AN XY:
74418
show subpopulations
African (AFR)
AF:
0.00106
AC:
44
AN:
41526
American (AMR)
AF:
0.00360
AC:
55
AN:
15286
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.000193
AC:
1
AN:
5178
South Asian (SAS)
AF:
0.00187
AC:
9
AN:
4818
European-Finnish (FIN)
AF:
0.000378
AC:
4
AN:
10594
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.000456
AC:
31
AN:
68014
Other (OTH)
AF:
0.00426
AC:
9
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
8
16
24
32
40
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0000280
Hom.:
0
Bravo
AF:
0.00144
ExAC
AF:
0.000601
AC:
73
EpiCase
AF:
0.000164
EpiControl
AF:
0.000771

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:5Benign:2
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities Uncertain:2
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.

Aug 31, 2021
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces valine with phenylalanine at codon 418 of the GAD1 protein (p.Val418Phe). The valine residue is moderately conserved and there is a small physicochemical difference between valine and phenylalanine. This variant is present in population databases (rs143058194, ExAC 0.08%). This missense change has been observed in individual(s) with GAD1-related disease (PMID: 28832565). ClinVar contains an entry for this variant (Variation ID: 332237). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

not provided Uncertain:1Benign:1
Breakthrough Genomics, Breakthrough Genomics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:not provided

Aug 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

GAD1: BP4, BS2

Inborn genetic diseases Uncertain:1
Feb 07, 2024
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.1252G>T (p.V418F) alteration is located in exon 13 (coding exon 12) of the GAD1 gene. This alteration results from a G to T substitution at nucleotide position 1252, causing the valine (V) at amino acid position 418 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

Hereditary spastic paraplegia Uncertain:1
Mar 07, 2017
Unit for Genetic & Epidemiological Research on Neurological Disorders, Instituto de Investigação e Inovação em Saúde
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:research

GAD1-related disorder Benign:1
May 18, 2022
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.21
BayesDel_addAF
Benign
-0.26
T
BayesDel_noAF
Benign
-0.21
CADD
Benign
22
DANN
Uncertain
0.98
DEOGEN2
Benign
0.29
T
Eigen
Benign
0.14
Eigen_PC
Benign
0.13
FATHMM_MKL
Uncertain
0.91
D
LIST_S2
Uncertain
0.96
D
M_CAP
Benign
0.040
D
MetaRNN
Benign
0.20
T
MetaSVM
Benign
-0.92
T
MutationAssessor
Benign
1.8
L
PhyloP100
1.8
PrimateAI
Benign
0.47
T
PROVEAN
Benign
-0.15
N
REVEL
Benign
0.26
Sift
Benign
0.39
T
Sift4G
Benign
0.34
T
Polyphen
0.98
D
Vest4
0.83
MVP
0.86
MPC
1.6
ClinPred
0.025
T
GERP RS
3.1
Varity_R
0.34
gMVP
0.94
Mutation Taster
=40/60
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs143058194; hg19: chr2-171709291; API